Skin events (SE) among 1,126 patients (Pts) treated with lapatinib (L), an oral dual ErbB1/2 tyrosine kinase inhibitor (TKI) - Sweetman, R (Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I., 2007)
No. 18S (June 20 Supplement)